Cargando…
CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine
Temporal association between BNT162b2 mRNA COVID-19 vaccine and myocarditis (PCVM) has been reported. We herein present early and 6-month clinical follow-up and cardiac magnetic resonance imaging (CMR) of patients with PVCM. A retrospective collection of data from 15 patients with PCVM and abnormal...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941830/ https://www.ncbi.nlm.nih.gov/pubmed/35320390 http://dx.doi.org/10.1007/s00246-022-02878-0 |
_version_ | 1784673184339984384 |
---|---|
author | Amir, Gabriel Rotstein, Amichai Razon, Yaron Beyersdorf, Gil Beer Barak–Corren, Yuval Godfrey, Max E. Lakovsky, Yaniv Yaeger-Yarom, Gili Yarden-Bilavsky, Havazelet Birk, Einat |
author_facet | Amir, Gabriel Rotstein, Amichai Razon, Yaron Beyersdorf, Gil Beer Barak–Corren, Yuval Godfrey, Max E. Lakovsky, Yaniv Yaeger-Yarom, Gili Yarden-Bilavsky, Havazelet Birk, Einat |
author_sort | Amir, Gabriel |
collection | PubMed |
description | Temporal association between BNT162b2 mRNA COVID-19 vaccine and myocarditis (PCVM) has been reported. We herein present early and 6-month clinical follow-up and cardiac magnetic resonance imaging (CMR) of patients with PVCM. A retrospective collection of data from 15 patients with PCVM and abnormal CMR was performed. Clinical manifestation, laboratory data, hospitalizations, treatment protocols, and imaging studies were collected early (up to 2 months) and later. In nine patients, an additional CMR evaluation was performed 6 months after diagnosis. PCVM was diagnosed in 15 patients, mean age 17 ± 1 (median 17.2, range 14.9–19 years) years, predominantly in males. Mean time from vaccination to onset of symptoms was 4.4 ± 6.7 (median 3, range 0–28) days. All patients had CMR post diagnosis at 4 ± 3 (median 3, range 1–9) weeks, 4/5 patients had hyper enhancement on the T2 sequences representing edemaQuery, and 12 pathological Late glandolinium enhancement. A repeat scan performed after 5–6 months was positive for scar formation in 7/9 patients. PCVM is a rare complication, affecting predominantly males and appearing usually within the first week after administration of the second dose of the vaccine. It usually is a mild disease, with clinical resolution with anti-inflammatory treatment. Late CMR follow up demonstrated resolution of the edema in all patients, while some had evidence of residual myocardial scarring. |
format | Online Article Text |
id | pubmed-8941830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-89418302022-03-24 CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine Amir, Gabriel Rotstein, Amichai Razon, Yaron Beyersdorf, Gil Beer Barak–Corren, Yuval Godfrey, Max E. Lakovsky, Yaniv Yaeger-Yarom, Gili Yarden-Bilavsky, Havazelet Birk, Einat Pediatr Cardiol Original Article Temporal association between BNT162b2 mRNA COVID-19 vaccine and myocarditis (PCVM) has been reported. We herein present early and 6-month clinical follow-up and cardiac magnetic resonance imaging (CMR) of patients with PVCM. A retrospective collection of data from 15 patients with PCVM and abnormal CMR was performed. Clinical manifestation, laboratory data, hospitalizations, treatment protocols, and imaging studies were collected early (up to 2 months) and later. In nine patients, an additional CMR evaluation was performed 6 months after diagnosis. PCVM was diagnosed in 15 patients, mean age 17 ± 1 (median 17.2, range 14.9–19 years) years, predominantly in males. Mean time from vaccination to onset of symptoms was 4.4 ± 6.7 (median 3, range 0–28) days. All patients had CMR post diagnosis at 4 ± 3 (median 3, range 1–9) weeks, 4/5 patients had hyper enhancement on the T2 sequences representing edemaQuery, and 12 pathological Late glandolinium enhancement. A repeat scan performed after 5–6 months was positive for scar formation in 7/9 patients. PCVM is a rare complication, affecting predominantly males and appearing usually within the first week after administration of the second dose of the vaccine. It usually is a mild disease, with clinical resolution with anti-inflammatory treatment. Late CMR follow up demonstrated resolution of the edema in all patients, while some had evidence of residual myocardial scarring. Springer US 2022-03-23 2022 /pmc/articles/PMC8941830/ /pubmed/35320390 http://dx.doi.org/10.1007/s00246-022-02878-0 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Amir, Gabriel Rotstein, Amichai Razon, Yaron Beyersdorf, Gil Beer Barak–Corren, Yuval Godfrey, Max E. Lakovsky, Yaniv Yaeger-Yarom, Gili Yarden-Bilavsky, Havazelet Birk, Einat CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine |
title | CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine |
title_full | CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine |
title_fullStr | CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine |
title_full_unstemmed | CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine |
title_short | CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine |
title_sort | cmr imaging 6 months after myocarditis associated with the bnt162b2 mrna covid-19 vaccine |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941830/ https://www.ncbi.nlm.nih.gov/pubmed/35320390 http://dx.doi.org/10.1007/s00246-022-02878-0 |
work_keys_str_mv | AT amirgabriel cmrimaging6monthsaftermyocarditisassociatedwiththebnt162b2mrnacovid19vaccine AT rotsteinamichai cmrimaging6monthsaftermyocarditisassociatedwiththebnt162b2mrnacovid19vaccine AT razonyaron cmrimaging6monthsaftermyocarditisassociatedwiththebnt162b2mrnacovid19vaccine AT beyersdorfgilbeer cmrimaging6monthsaftermyocarditisassociatedwiththebnt162b2mrnacovid19vaccine AT barakcorrenyuval cmrimaging6monthsaftermyocarditisassociatedwiththebnt162b2mrnacovid19vaccine AT godfreymaxe cmrimaging6monthsaftermyocarditisassociatedwiththebnt162b2mrnacovid19vaccine AT lakovskyyaniv cmrimaging6monthsaftermyocarditisassociatedwiththebnt162b2mrnacovid19vaccine AT yaegeryaromgili cmrimaging6monthsaftermyocarditisassociatedwiththebnt162b2mrnacovid19vaccine AT yardenbilavskyhavazelet cmrimaging6monthsaftermyocarditisassociatedwiththebnt162b2mrnacovid19vaccine AT birkeinat cmrimaging6monthsaftermyocarditisassociatedwiththebnt162b2mrnacovid19vaccine |